Evidence map›Paper›PMID 40016722›Full record

ArticleRespiratory research2025

Complement activity and autophagy are dysregulated in the lungs of patients with nonresolvable COVID-19 requiring lung transplantation.

Pooja Shivshankar, Stacey L Mueller-Ortiz, Aleksey Y Domozhirov, Weizhen Bi, Scott D Collum, Marie-Francoise Doursout, Manish Patel, Isabella N LeFebvre, Bindu Akkanti, Simon Yau and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Pooja Shivshankar *Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX, USA. Pooja.Shivshankar@uth.tmc.edu.
Stacey L Mueller-Ortiz *Hans J. Müller-Eberhard and Irma Gigli Center for Immunology and Autoimmune Diseases, Institute of Molecular Medicine, UTHealth-McGovern Medical School, Houston, TX, USA.
Aleksey Y DomozhirovHans J. Müller-Eberhard and Irma Gigli Center for Immunology and Autoimmune Diseases, Institute of Molecular Medicine, UTHealth-McGovern Medical School, Houston, TX, USA.
Weizhen BiDepartment of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX, USA.
Scott D CollumDepartment of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX, USA.
Marie-Francoise DoursoutDepartment of Anesthesiology, Houston, TX, USA.
Manish PatelCenter for Advanced Cardiopulmonary Therapies and Transplantation at UTHealth/McGovern Medical School, Houston, TX, USA.
Isabella N LeFebvreCenter for Advanced Cardiopulmonary Therapies and Transplantation at UTHealth/McGovern Medical School, Houston, TX, USA.
Bindu AkkantiDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, 6431 Fannin Street, Suite 6.214, Houston, TX, 77030, USA.
Simon YauHouston Methodist DeBakey Transplant Center, Houston Methodist Hospital, Houston, TX, USA.
Howard J HuangHouston Methodist DeBakey Transplant Center, Houston Methodist Hospital, Houston, TX, USA.
Rahat HussainCenter for Advanced Cardiopulmonary Therapies and Transplantation at UTHealth/McGovern Medical School, Houston, TX, USA.
Harry Karmouty-QuintanaDepartment of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX, USA. Harry.Karmouty@uth.tmc.edu.

Funding

3'UTR Shortening In Pulmonary Vascular DiseaseR01HL138510 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARMOUTY-QUINTANA, HARRY · 2017 to 2021
$2.3M
Complement and Circadian Interactions in Inflammation and ImmunityR01AI158694 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MAHAN, KRISTIN ECKEL, SHIVSHANKAR, POOJA · 2021 to 2025
$1.9M
NHLBI NIH HHS 1R01HL138510NHLBI NIH HHS R01 HL138510NIAID NIH HHS R01 AI158694
6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19) pandemic has challenged the current understanding of the complement cascade mechanisms of host immune responses during infection-induced nonresolvable lung disease. While the complement system is involved in opsonization and phagocytosis of the invading pathogens, uncontrolled complement activation also leads to aberrant autophagic response and tissue damage. Our recent study revealed unique pathologic and fibrotic signature genes associated with epithelial bronchiolization in the lung tissues of patients with nonresolvable COVID-19 (NR-COVID-19) requiring lung transplantation. However, there is a knowledge gap if complement components are modulated to contribute to tissue damage and the fibrotic phenotype during NR-COVID-19. We, therefore, aimed to study the role of the complement factors and their corresponding regulatory proteins in the pathogenesis of NR-COVID-19. We further examined the association of complement components with mediators of the host autophagic response. We observed significant upregulation of the expression of the classical pathway factor C1qrs and alternative complement factors C3 and C5a, as well as the anaphylatoxin receptor C5aR1, in NR-COVID-19 lung tissues. Of note, complement regulatory protein, decay accelerating factor (DAF; CD55) was significantly downregulated at both transcript and protein levels in the NR-COVID-19 lungs, indicating a dampened host protective response. Furthermore, we observed significantly decreased levels of the autophagy mediators PPARγ and LC3a/b, which was corroborated by decreased expression of factor P and the C3b receptor CR1, indicating impaired clearance of damaged cells that may contribute to the fibrotic phenotype in NR-COVID-19 patients. Thus, our study revealed previously unrecognized complement dysregulation associated with impaired cell death and clearance of damaged cells, which may promote NR-COVID-19 in patients, ultimately necessitating lung transplantation. The identified network of dysregulated complement cascade activity indicates the interplay of regulatory factors and the receptor-mediated modulation of host immune and autophagic responses as potential therapeutic targets for treating NR-COVID-19.

Indexed as

AutophagyComplement ActivationComplement System ProteinsCOVID-19LungLung TransplantationAdultAgedFemaleHumansMaleMiddle AgedSARS-CoV-2Complement System ProteinsAutophagyC3a and C5a anaphylatoxinsComplement activationComplement-mediated immunityNonresolvable COVID-19Pulmonary fibrosisReceptor signaling

Identifiers

PMID40016722
PMCPMC11866606

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.